Appendix 4E and Annual Report
Filed with ASX · · 52 pages · English
Summary by 6ix AI
The report indicates a decline in revenues from ordinary activities and other income, alongside an increase in the loss attributable to the owners of Syntara Limited. No dividends were declared or paid during the current financial period. The report also highlights significant advancements in Syntara's clinical pipeline, particularly with its lead candidate amsulostat.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Syntara
- Appendix 4G and Corporate Governance Statement
- Investor Update Webinar Presentation
- Encouraging SNT-4728 Phase 2 iRBD results
- Results of Share Purchase Plan
- Share Purchase Plan Offer Booklet
Later from Syntara
- Notification of 2026 AGM Date
- Application for quotation of securities - SNT
- Syntara receives A$4.7m R&D Tax Incentive
- Syntara expands SNT-9465 skin scarring study
- Notification regarding unquoted securities - SNT
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara